CoChat

Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis

Open access
Gungabissoon, Usha, Gibbons, Daniel C, Requena, Gema, Ribeiro de Souza, Andrea, Smith, Helen · 2022 · BMJ Open Gastroenterology

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Objective: In order to identify areas of unmet need in patients with primary biliary cholangitis (PBC), this study sought to use real-world observational healthcare data to characterise the burden in patients with PBC and in PBC patients with a recorded diagnosis of pruritus. Design: This retrospective, cross-sectional database study compared prevalence of prespecified comorbidities and medications in the PBC population and PBC-pruritus subpopulation with non-cases using an indirect standardisation approach. The PBC population was identified from the US IBM MarketScan Commercial Claims and Medicare Supplemental Database during 2016 using International Classification of Diseases 10th Revision, Clinical Modification codes (≥2 claims for PBC); the PBC-pruritus subpopulation additionally had ≥1 claim for pruritus during this period. Non-cases had no claims for PBC. Indirect age-sex standardised prevalence ratios (iSPR) and 95% confidence intervals (CIs) were calculated for prespecified comorbidities and medications recorded during 2017. Results: The PBC population (N=1963) and PBC-pruritus subpopulation (N=139) had significantly higher prevalence of fatigue (19.9%, iSPR (95% CI): 1.51 (1.36 to 1.66); 26.6%, 2.10 (1.48 to 2.90)), depression/anxiety (21.3%, 1.09 (0.99 to 1.20); 28.1%, 1.46 (1.04 to 2.00)) and sleep-related issues (6.9%, 1.18 (0.99 to 1.40); 14.4%, 2.58 (1.58 to 3.99)) compared with non-cases. Bile acid sequestrants were prescribed in 5.8% and 18.0% of the PBC and PBC-pruritus populations, respectively. In general, a higher prevalence of comorbidities and medication use was observed in the PBC-pruritus subpopulation compared with the PBC population and non-cases. Conclusion: Despite availability of treatments for PBC, the PBC population had a higher burden of comorbidities than non-cases. This burden was even greater among the PBC-pruritus subpopulation, with a particularly high prevalence of sleep disorders and depression/anxiety. Despite this, pruritus remains undertreated highlighting a need for treatments specifically indicated for cholestatic pruritus.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjgast-2021-000857

Cites

33 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Age distribution in the PBC population (N=1963) and the PBC-pruritus subpopulation (N=139). PBC, primary biliary cholangitis.
Figure 1 Age distribution in the PBC population (N=1963) and the PBC-pruritus subpopulation (N=139). PBC, primary biliary cholangitis.CC BY-NC · PubMed Central
Figure 2 Prevalence of prespecified comorbidities among (A) patients in the PBC population (N=1963) or (B) the PBC-pruritus subpopulation (N=139) relative to the respective non-case populations*. *Ns for the non-case population differs between analysis A and B: non-cases for analysis A (PBC population) N=10 245 592; non-cases for analysis B (PBC-pruritus subpopulation) N=9 984 009. Prevalence of prespecified comorbidities in the PBC population or the PBC-pruritus subpopulation, using prevalence in the non-case population as reference. iSPRs ˃1 imply greater prevalence in either of the PBC case populations versus the non-case population. Crude point prevalence (%) and iSPRs (95% CIs) for each of the comorbidities shown are also reported in table 1. iSPRs, indirect age-sex standardised prevalence ratios; PBC, primary biliary cholangitis; SLE, systemic lupus erythematosus; UTI, urinary tract infection.
Figure 2 Prevalence of prespecified comorbidities among (A) patients in the PBC population (N=1963) or (B) the PBC-pruritus subpopulation (N=139) relative to the respective non-case populations*. *Ns for the non-case population differs between analysis A and B: non-cases for analysis A (PBC population) N=10 245 592; non-cases for analysis B (PBC-pruritus subpopulation) N=9 984 009. Prevalence of prespecified comorbidities in the PBC population or the PBC-pruritus subpopulation, using prevalence in the non-case population as reference. iSPRs ˃1 imply greater prevalence in either of the PBC case populations versus the non-case population. Crude point prevalence (%) and iSPRs (95% CIs) for each of the comorbidities shown are also reported in table 1. iSPRs, indirect age-sex standardised prevalence ratios; PBC, primary biliary cholangitis; SLE, systemic lupus erythematosus; UTI, urinary tract infection.CC BY-NC · PubMed Central
Figure 3 Prevalence of prespecified medications among (A) patients in the PBC population (N=1963) or (B) the PBC-pruritus subpopulation (N=139) relative to the respective non-case populations*. *Ns for the non-case population differs between analysis A and B: non-cases for analysis A (PBC population) N=10 245 592; non-cases for analysis B (PBC-pruritus subpopulation) N=9 984 009. Prevalence of prespecified medications in the PBC population or the PBC-pruritus subpopulation, using prevalence in the non-case population as reference. iSPRs ˃1 imply greater medication prevalence in either of the PBC case populations versus the PBC non-case population. Crude point prevalence (%) and iSPRs (95% CIs) for each of the medications shown are also reported in table 2.iSPRs, indirect age-sex standardised prevalence ratios; PBC, primary biliary cholangitis; MMF, mycophenolate mofetil.
Figure 3 Prevalence of prespecified medications among (A) patients in the PBC population (N=1963) or (B) the PBC-pruritus subpopulation (N=139) relative to the respective non-case populations*. *Ns for the non-case population differs between analysis A and B: non-cases for analysis A (PBC population) N=10 245 592; non-cases for analysis B (PBC-pruritus subpopulation) N=9 984 009. Prevalence of prespecified medications in the PBC population or the PBC-pruritus subpopulation, using prevalence in the non-case population as reference. iSPRs ˃1 imply greater medication prevalence in either of the PBC case populations versus the PBC non-case population. Crude point prevalence (%) and iSPRs (95% CIs) for each of the medications shown are also reported in table 2.iSPRs, indirect age-sex standardised prevalence ratios; PBC, primary biliary cholangitis; MMF, mycophenolate mofetil.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Research works printed but not linked: 2

  1. Jones DE . Primary biliary cholangitis. BMJ best practice. Available: https://bestpractice.bmj.com/topics/en-gb/344
  2. Carey, 2020, The pervasive impact of pruritus on quality of life in patients with primary biliary cholangitis (PBC): real world experience in TARGET-PBC, Hepatology, 72, 766A

Cited by

See all 20

Metadata

Authors
Gungabissoon, U., Gibbons, D. C., Requena, G., Ribeiro de Souza, A., & Smith, H.
Affiliations
  • GlaxoSmithKline (United Kingdom) (GB)
  • Value Evidence and Outcomes (Real World Analytics), GSK, Brentford, UK
  • Research and Development, GSK, Madrid, Spain
  • Value Evidence and Outcomes (Specialty), GSK, Brentford, UK
Corresponding author
Gungabissoon, Usha
Venue
BMJ Open Gastroenterology
Publisher
BMJ
Published
2022-08
Volume
9
Issue
1
Pages
e000857
ISSN
2054-4774 (ISSN-L)
OpenAlex
W4292056559
Cited by
20
References
33
Citations by year
2026: 5 · 2025: 8 · 2024: 6 · 2023: 1
FWCI
2.23
Type
journal article
Language
en
Open access
Locations
  • BMJ Open Gastroenterology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
GlaxoSmithKline (GSK212487/209984)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Gastroenterology › Gallbladder and Bile Duct Disorders
Keywords
primary biliary cirrhosis, pruritus, disease burden, comorbidities, fatigue, anxiety and depression, bile acid sequestrants, medication use, unmet medical needs, claims data, real-world evidence, commercial claims, United States patients
MeSH terms
Aged, Medicare, Humans, Insurance Claim Review, Liver Cirrhosis, Biliary, Pruritus, Retrospective Studies, United States, Cost of Illness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis. https://app.cochat.ai/papers/10.1136/bmjgast-2021-000857
The paper
Gungabissoon, U., Gibbons, D. C., Requena, G., Ribeiro de Souza, A., & Smith, H. (2022). Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis. BMJ Open Gastroenterology. https://doi.org/10.1136/bmjgast-2021-000857

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.